Karyopharm Therapeutics Inc. and Clinipace Worldwide Announce Preferred Provider Agreement

Apr 09, 2014
By Applied Clinical Trials Editors

Clinipace Worldwide announced it has entered into a preferred provider agreement with Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The preferred provider agreement is part of a longer-term strategic partnership that would see Clinipace managing several clinical programs, including oncology, wound healing, and other diseases, on behalf of Karyopharm in 2014.

Read the full release here.

lorem ipsum